Elicio Therapeutics
NASDAQ · ELTX·Boston, MA·Small-cap·Phase 2
Clinical-stage immuno-oncology company developing lymph node-targeted Amphiphile (AMP) cancer vaccines. Lead asset ELI-002 7P targets seven mutant KRAS variants and is in Phase 2 (AMPLIFY-7P) for minimal residual disease in pancreatic ductal adenocarcinoma.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Elicio Therapeutics Corporate Deck — January 2026 | Corporate overview | January 15, 2026 | 50 |